HB 3082
Requires prescription drug manufacturers to report to the Department of Consumer and Business Services the total number of consumers to which the manufacturer offered a patient assistance program who participated in the program, notwithstanding any increase in the price of the prescription drug for which the manufacturer offered the program.
Jurisdiction
Oregon
Session
2025 Regular Session
Committee
Behavioral Health and Health Care
Take action
Record your position on this measure.
Sign in to record your position, submit testimony, or contact your legislator.
Sign in to take actionPublic sentiment
Support
75%
Oppose
25%
- Introduced
- Passed House
- Passed Senate
- To Governor
- Became Law
Bill overview
This bill requires prescription drug manufacturers to report to the Department of Consumer and Business Services the details of their patient assistance programs, including the number of participants and the value of assistance provided. It mandates these reports, even if the drug price hasn’t increased. The bill also seeks to gather more data on drug pricing, including manufacturing costs, research and development expenses, and sales revenue, and requires manufacturers to disclose this information to the department. Finally, it establishes a process for consumers to report price increases and requires the department to share this information with the Prescription Drug Affordability Board.
Key provisions
- Manufacturers must report the number of patients participating in patient assistance programs, regardless of price increases.
- Manufacturers must report the value of coupons, discounts, and copayment assistance provided through patient assistance programs.
- Manufacturers must report detailed information about drug pricing, including manufacturing costs, R&D expenses, and sales revenue.
- Manufacturers must disclose the length of time a drug has been on the market and the availability of generic versions.
- Manufacturers must notify the department of new drugs exceeding a certain price threshold.
- The department can request supporting documentation from manufacturers.
- A civil penalty may be imposed for failing to comply with reporting requirements.
- The department will post reports and requests for information on its website.
Who is affected
Sponsors
Official sponsors from legislative records.
Primary sponsor
Emerson Levy
Cosponsors
Arguments in favor
Reasons to support this legislation.
Many supporters believe that a system allowing patients to use co-pay assistance provided by pharmaceutical manufacturers to meet their annual deductible would significantly reduce reliance on emergency room care, thereby improving health outcomes and ensuring Oregonians can access life-saving medication without financial burden. This approach is supported by policymakers who see the value in gaining insight into the role and impact of drug assistance programs on the state's population, as proposed by HB 3082. By addressing affordability concerns and promoting more effective use of existing resources, supporters argue that this system would ultimately benefit Oregonians' access to essential medication and overall well-being.
Source: Testimony Summaries
Arguments opposed
Reasons to oppose this legislation.
Opponents of HB 3082 express concerns that expanding existing transparency laws in an uncertain manner could create a significant administrative burden on state agencies, potentially outweighing any potential benefits. They argue that the lack of clear guidance and standards would lead to inconsistent and unclear information, hindering effective decision-making and governance. Furthermore, critics contend that this approach would undermine the state's ability to efficiently manage its affairs, as it would introduce unnecessary complexity and uncertainty into existing systems.